NAV

Laninamivir辛酸酯

This drug entry is astuband has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Laninamivir辛酸酯
DrugBank Accession Number
DB11888
Background

Laninamivir辛酸酯has been used in trials studying the treatment of Asthma.

Type
Small Molecule
Groups
Investigational
Structure
MOL SDF PDB SMILES InChI
Similar Structures
Weight
Average: 472.5325
Monoisotopic: 472.253314148
Chemical Formula
C21H36N4O8
Synonyms
Not Available
External IDs
  • CS 8958
  • CS-8958
  • R-118958

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
看看
Build, train, & validate predictive machine-learning models with structured datasets.
看看
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information oncontraindications & blackbox warnings, population restrictions, harmful risks, & more.
了解更多
Avoid life-threatening adverse drug events & improve clinical decision support.
了解更多
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including:blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
了解更多
Improve decision support & research outcomes with our structured adverse effects data.
了解更多
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRsBrowse all" title="" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug InteractionsLearn More" title="" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction
Integrate drug-drug
interactions in your software
Adenovirus type 7 vaccine live The therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Laninamivir octanoate.
Anthrax vaccine The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Laninamivir octanoate.
Bacillus calmette-guerin substrain connaught live antigen The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Laninamivir octanoate.
Bacillus calmette-guerin substrain russian BCG-I live antigen The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Laninamivir octanoate.
Bacillus calmette-guerin substrain tice live antigen The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Laninamivir octanoate.
BCG vaccine The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Laninamivir octanoate.
Human adenovirus e serotype 4 strain cl-68578 antigen The therapeutic efficacy of Human adenovirus e serotype 4 strain cl-68578 antigen can be decreased when used in combination with Laninamivir octanoate.
Rubella virus vaccine The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Laninamivir octanoate.
Typhoid Vaccine Live The therapeutic efficacy of Typhoid Vaccine Live can be decreased when used in combination with Laninamivir octanoate.
Varicella zoster vaccine (live/attenuated) The therapeutic efficacy of Varicella zoster vaccine (live/attenuated) can be decreased when used in combination with Laninamivir octanoate.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
了解更多
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided byClassyfire
Description
This compound belongs to the class of organic compounds known as fatty acid esters. These are carboxylic ester derivatives of a fatty acid.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Fatty Acyls
Sub Class
Fatty acid esters
Direct Parent
Fatty acid esters
Alternative Parents
Dicarboxylic acids and derivatives/Acetamides/Secondary carboxylic acid amides/二级醇/Guanidines/Carboxylic acid esters/Propargyl-type 1,3-dipolar organic compounds/Oxacyclic compounds/Dialkyl ethers/Carboxylic acids
show 4 more
Substituents
Acetamide/Alcohol/Aliphatic heteromonocyclic compound/Carbonyl group/Carboxamide group/Carboximidamide/Carboxylic acid/Carboxylic acid derivative/Carboxylic acid ester/Dialkyl ether
show 16 more
分子Framework
Aliphatic heteromonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
E026V904RL
CAS number
203120-46-1
InChI Key
UKTIJASCFRNWCB-RMIBSVFLSA-N
InChI
InChI=1S/C21H36N4O8/c1-4-5-6-7-8-9-16(28)32-11-14(27)18(31-3)19-17(24-12(2)26)13(25-21(22)23)10-15(33-19)20(29)30/h10,13-14,17-19,27H,4-9,11H2,1-3H3,(H,24,26)(H,29,30)(H4,22,23,25)/t13-,14+,17+,18+,19+/m0/s1
国际命名
(2R,3R,4S)-4-carbamimidamido-3-acetamido-2-[(1R,2R)-2-hydroxy-1-methoxy-3-(octanoyloxy)propyl]-3,4-dihydro-2H-pyran-6-carboxylic acid
SMILES
[H][C@]1(OC(=C[C@H](NC(N)=N)[C@H]1NC(C)=O)C(O)=O)[C@H](OC)[C@H](O)COC(=O)CCCCCCC

References

General References
Not Available
PubChem Compound
9847629
PubChem Substance
347828223
ChemSpider
8023342
ChEBI
134741
ChEMBL
CHEMBL467058
ZINC
ZINC000014175798
PDBe Ligand
LVO
PDB Entries
3ti4/3tib

Clinical Trials

Clinical TrialsLearn More" title="" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count
3 Completed Treatment Influenza, Human 1
2 Completed Treatment Flu caused by Influenza 1
1 Completed Prevention Flu caused by Influenza 1
1 Completed Treatment Asthma 1
1 Completed Treatment Flu caused by Influenza 2
1, 2 Terminated Treatment Flu caused by Influenza 1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
Property Value Source
Water Solubility 0.184 mg/mL ALOGPS
logP 0.86 ALOGPS
logP -1.8 Chemaxon
logS -3.4 ALOGPS
pKa (Strongest Acidic) 2.96 Chemaxon
pKa (Strongest Basic) 11.54 Chemaxon
Physiological Charge 0 Chemaxon
Hydrogen Acceptor Count 10 Chemaxon
Hydrogen Donor Count 6 Chemaxon
Polar Surface Area 193.29 Å2 Chemaxon
Rotatable Bond Count 15 Chemaxon
Refractivity 128.02 m3·mol-1 Chemaxon
Polarizability 49.12 Å3 Chemaxon
Number of Rings 1 Chemaxon
Bioavailability 0 Chemaxon
Rule of Five No Chemaxon
Ghose Filter No Chemaxon
Veber's Rule No Chemaxon
MDDR-like Rule No Chemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Spectrum Spectrum Type Splash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available

Drug created at October 20, 2016 20:57 / Updated at June 12, 2020 16:53